Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYR-064 for PD-Related Hyposmia
NCT06498687Phase 1Withdrawn
- Sponsor
- University of Nebraska
- Start
- Apr 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of theophylline in Hyposmia and anosmia, sponsored by University of Nebraska. Primary endpoints: Numeric Rating Scale-11 Smell-Patient Reported Outcome (PRO): Improvement at 24 weeks, Numeric Rating Scale-11 Taste-Patient Reported Outcome (PRO): Improvement at 24 weeks and 2 more. Planned start Apr 2025; status: withdrawn.
02
Drugs
theophylline
03
Conditions
Hyposmiaanosmia
Beyond the preview
Go deeper on NCT06498687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06498687.